Gilead says Trodelvy-Keytruda combo effective for aggressive breast cancer type
Gilead Sciences said on Monday a late-stage study showed that its drug Trodelvy used in combination with Merck's immunotherapy Keytruda significantly slowed disease progression in patients with an ...
What Analyst Projections for Key Metrics Reveal About Gilead (GILD) Q1 Earnings
Evaluate the expected performance of Gilead (GILD) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics ...
Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?
Gilead Sciences' leading HIV business might face a slowdown in 2025, even though a potential approval of lenacapavir would be a significant boost. We recommend investors to wait and watch for now.
Gilead Sciences: 4 Reasons This Stock Has Much More To Rise
Gilead Sciences Inc. NASDAQ: GILD stock surged to a new 52-week high at $106.69 recently on its fourth quarter of 2024 earnings release. After being asleep for so many years, the stock has finally ...
Gilead Stock Rises 8% Post Q4 Earnings: Should You Buy or Sell?
GILD's strong HIV portfolio should maintain momentum for the company. The guidance for 2025 is impressive.
Gilead Sciences, Inc. (GILD) Q4 2024 Earnings Call Transcript
Gilead Sciences, Inc. (NASDAQ:GILD ) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Company Participants Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercie...
Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street est...
Gilead Sciences: Diversification Strategy Not Derisked Enough Yet
Gilead Sciences: Diversification Strategy Not Derisked Enough Yet
Gilead Sciences to Report Q4 Earnings: Is a Beat in the Cards?
Investors' focus will likely be on GILD's HIV franchise performance and oncology sales when the company reports fourth-quarter 2024 results.
Ahead of Gilead (GILD) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Gilead (GILD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quart...
Gilead Sciences (GILD) Surpasses Market Returns: Some Facts Worth Knowing
Gilead Sciences (GILD) closed at $99.65 in the latest trading session, marking a +1.69% move from the prior day.
Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?
Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
GILD vs. ALNY: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Gilead Sciences (GILD) and Alnylam Pharmaceuticals (ALNY). But which of these two sto...
Can Gilead Sciences Sustain Its Growth Momentum in 2025?
GILD has performed well in the past six months, with new drug approvals, positive data readouts and strong quarterly results. While the fundamentals look solid, we advise investors to remain on the...
Gilead Sciences, US government settle patent case over HIV prevention drugs
Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware federal court.
Related Companies